Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Home Gains Buoy Cipla In Q1 But US Momentum Pivotal

Executive Summary

A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.

You may also be interested in...

Cipla Warns Of Tough 2H - Pressure On Tender Business, Sanctions-Related Volatility

Cipla rang in a “modest” Q2 and management has cautioned that coming quarters might see significant headwinds including the impact of a constrained funding environment on the tender business and US sanctions-related turbulence in some markets.

India Pharma Firms Eye China, Dr Reddy’s Sees ‘Great Opportunity’ There

Dr Reddy’s Laboratories appears to be the among the Indian firms considering increasing its activities in China, enthused by the evolving regulatory environment and consequent market opportunities there. The Indian company believes a large basket of products could meet China’s new norms.

Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug

Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts